Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics
about
SYK is a critical regulator of FLT3 in acute myeloid leukemiaActivity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITDInternal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic LeFLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitationsClinical outcome of de novo acute myeloid leukaemia patients with normal cytogenetics is affected by molecular genetic alterations: a concise reviewGamma-secretase represents a therapeutic target for the treatment of invasive glioma mediated by the p75 neurotrophin receptorDiscovery of a Diaminopyrimidine FLT3 Inhibitor Active against Acute Myeloid Leukemia.A Phase II trial of tandutinib (MLN 518) in combination with bevacizumab for patients with recurrent glioblastoma.Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia.Emerging FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myelogenous leukemiaPhase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor.Small-molecule inhibitors of the receptor tyrosine kinases: promising tools for targeted cancer therapiesFLT3-regulated antigens as targets for leukemia-reactive cytotoxic T lymphocytes.Neuromuscular junction toxicity with tandutinib induces a myasthenic-like syndromeIdentification of somatic and germline mutations using whole exome sequencing of congenital acute lymphoblastic leukemia.Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens.Treatment of FLT3-ITD acute myeloid leukemia.Dose study of the multikinase inhibitor, LY2457546, in patients with relapsed acute myeloid leukemia to assess safety, pharmacokinetics, and pharmacodynamicsComputer-guided design, synthesis, and biological evaluation of quinoxalinebisarylureas as FLT3 inhibitors.Targeted Therapy of FLT3 in Treatment of AML-Current Status and Future Directions.Targeting MCL-1 sensitizes FLT3-ITD-positive leukemias to cytotoxic therapies.Midostaurin does not prolong cardiac repolarization defined in a thorough electrocardiogram trial in healthy volunteersTargeting CDK1 promotes FLT3-activated acute myeloid leukemia differentiation through C/EBPα.Notch signaling in developmental and tumor angiogenesis.Effects of Toll-like receptor signals in T-cell neoplasms.Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML.High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia.Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutationFuture options for imatinib mesilate-resistant tumors.Treatment options for the management of acute leukaemia relapsing following an allogeneic transplant.Detection of FLT3 oncogene mutations in acute myeloid leukemia using conformation sensitive gel electrophoresis.Antiangiogenic therapy in brain tumors.Molecular and chromosomal alterations: new therapies for relapsed acute myeloid leukemia.Targeting FLT3 for the treatment of leukemiaMolecular targeting of MLL-rearranged leukemia cell lines with the synthetic peptide PFWT synergistically enhances the cytotoxic effect of established chemotherapeutic agents.ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside.AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)Mechanisms of resistance to FLT3 inhibitors.Genomic approaches to small molecule discovery.
P2860
Q24337247-B948CE50-71A1-4112-B130-7E0BD6C7CB66Q27852087-0B421FD1-7B80-4023-94D4-A08B3EBAC6AEQ27853031-77BCF595-2193-4B90-AA91-BD1B54909B8BQ28289859-EF23DBE6-C068-4B75-A708-54DC6C8732D2Q28301344-4E81CC32-79E3-4B89-8FB3-151FFCA6F12EQ33391513-28421625-D483-4189-855B-CE1F0F7395B7Q33749036-377B5EBF-8F7D-4BFD-AC9F-096919F55520Q33913465-31EF4E7A-ADFF-48EC-A647-793D5D0CF64BQ33986236-D50AFD84-11BE-417C-84AD-1C5852D66333Q34004131-19ED7F6D-5935-46EC-ABDB-F3203147F251Q34095013-537DE1A3-AC81-4244-975C-86167E3799ECQ34104338-5A5BA7E7-FA66-433F-AA35-FAFBCFF12065Q34158454-5720FF86-40B8-48A0-BB58-8AFA47AAB73FQ34350591-6A5FD61B-878B-42A0-94C0-DC6807B31160Q34555328-5E7D70BF-0523-4032-80E5-DB37A6302BDDQ34573775-8E81F26A-9EC9-4091-82A7-BAB4BA3B1068Q34591403-214433B3-0791-424C-AA32-4FEAD0F9D1B9Q34636735-FC1B34AA-815F-48B7-B4DC-39E44396E9BCQ35003666-6D19F3B6-A005-447C-9E5C-5B3FA32EFA23Q35560182-C3A4FB30-A2C7-44FC-9E36-B517520BED03Q35750567-E2741D81-52CD-4B1E-B71F-1265E3DA5D0FQ35865681-EA42F4E3-864E-44BE-84AD-0B93B1F6C6D5Q35914782-6D9D1BF6-88BC-4161-871C-8A9447B2881CQ36129030-FEE17D8A-FA8C-402E-A0B4-0CE33D3D84EBQ36137696-3F2C6D85-EB25-416B-9E4E-4F61987F2533Q36293678-A2C72680-5773-4523-B407-2C53F51279FFQ36410157-135A0375-7462-4813-ABF3-AA43B661F703Q36591388-7AF1CBC8-91C4-4487-9B8F-55F70ED678B9Q36907832-A98CC249-7100-498D-83AA-43AB1C167E5FQ36964688-BCD040CA-2168-4367-AAE3-50DBF423EC6BQ36977560-6D30F1D1-5315-459B-89E3-91CA17BBE476Q37083261-135964A5-55ED-40A5-B567-CCCE2BBFB10AQ37129915-AE5F330B-ACE5-487B-A2C1-023F382069F1Q37183513-15064392-565D-4F6F-88A8-F6BB7ACC2797Q37257308-BBB7ECFD-C9D3-4BCC-806D-7258E911B098Q37260555-347B7CCC-E19D-4B5A-8C54-3FF0ADD3BA65Q37312735-5AA1F5C7-D511-4917-895B-11D1E0EE93ADQ37373040-7276043F-DD21-4643-939E-0B85179722F0Q37375423-0D81DD8F-7C25-4329-B8F2-AD4948C1A98AQ37406963-B1D18957-7898-42BE-AF1C-AA4646E9D36E
P2860
Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Phase 1 clinical results with ...... kinetics, and pharmacodynamics
@ast
Phase 1 clinical results with ...... kinetics, and pharmacodynamics
@en
type
label
Phase 1 clinical results with ...... kinetics, and pharmacodynamics
@ast
Phase 1 clinical results with ...... kinetics, and pharmacodynamics
@en
prefLabel
Phase 1 clinical results with ...... kinetics, and pharmacodynamics
@ast
Phase 1 clinical results with ...... kinetics, and pharmacodynamics
@en
P2093
P2860
P50
P1433
P1476
Phase 1 clinical results with ...... kinetics, and pharmacodynamics
@en
P2093
Daniel J DeAngelo
Jean-Michel Lecerf
Mark L Heaney
Michael A Caligiuri
Michael D Karol
Michael R Cooper
Peter T Curtin
Rebecca B Klisovic
Richard M Stone
Ronald L Paquette
P2860
P304
P356
10.1182/BLOOD-2006-02-005702
P407
P577
2006-08-10T00:00:00Z